embecta names new Chairman of the Board and Lead Independent Director
Embecta Corp. (EMBC)
Company Research
Source: GlobeNewswire
PARSIPPANY, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today announced that the Board of Directors (the “Board”) of embecta has elected Devdatt “Dev” Kurdikar as Chairman of the Board and Dr. Claire Pomeroy as Lead Independent Director, effective immediately. These changes follow the previously announced retirement of LTG (Ret.) David F. Melcher, Non-Executive Chairman of the Board due to several commitments outside of his service to the Company. Kurdikar, 57, joined BD (Becton, Dickinson and Company) in 2021 to lead the diabetes care business and became the President and Chief Executive Officer of the company and a member of its Board of Directors upon completion of its spinoff from BD in 2022. He is also a member of the Board of Directors of Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), AdvaMed (Advanced Medical Te
Show less
Read more
Impact Snapshot
Event Time:
EMBC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EMBC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EMBC alerts
High impacting Embecta Corp. news events
Weekly update
A roundup of the hottest topics
EMBC
News
- Embecta (NASDAQ:EMBC) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=EMBC&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> MarketBeat
- Embecta (NASDAQ:EMBC) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $25.00 price target on the stock.MarketBeat
- Embecta Q1 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- Embecta Corp. (EMBC) Q1 2026 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Embecta outlines $1.71B–$1.93B revenue target for 2026 as GLP-1 partnerships gain traction [Seeking Alpha]Seeking Alpha
EMBC
Earnings
- 2/6/26 - Beat
EMBC
Sec Filings
- 2/5/26 - Form 10-Q
- 2/5/26 - Form 8-K
- 1/30/26 - Form SCHEDULE
- EMBC's page on the SEC website